Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

Earlier this month, Icosavax, a Seattle-based biotech company that originally launched from the University of Washington, filed for IPO.

Founded in 2017, Icosavax develops vaccines that mimic viruses to fight against infectious diseases.

“We believe that our pipeline and platform can deliver a meaningful impact globally in preventing life-threatening infectious diseases,” said Icosavax in its filing.

READ THE STORY at GeekWire »